Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma

Sandra Horning

Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction therapy, brought clear benefits among patients in the study.




Click here for all the interviews from ASH 2005

Targeted Therapies in Multiple Myeloma Treatment Decisions

Vincent Rajkumar

Vincent Rajkumar, Divison of Hematology, Mayo Clinic
At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkumar discussed new agents such as lenolidamide and thalidomide. Audio Medica asked him how he makes decisions about how to treat multiple myeloma.

Click here for all the interviews from ASH 2005

Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma

Owen O’Connor

Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other targeting the mTOR signaling pathway with a drug called temsirolimus.

Click here for all the interviews from ASH 2005